"FDA Approves Revolutionary Cell Therapy for Metastatic Melanoma"

The FDA has granted accelerated approval for the first cell therapy, Amtagvi or lifileucel, for treating advanced melanoma, marking a significant milestone in cancer treatment. This immunotherapy, developed by Iovance, involves harvesting cancer-fighting immune cells from the patient's own body. In a phase 2 clinical trial, 31% of patients who had exhausted standard care options responded to the therapy, with 42% of responders still showing positive results after 18 months. Researchers believe this approval could pave the way for similar successes in treating other solid tumors.